Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

59.86USD
24 Jun 2016
Change (% chg)

$-1.45 (-2.37%)
Prev Close
$61.31
Open
$59.49
Day's High
$60.59
Day's Low
$59.40
Volume
3,397,992
Avg. Vol
2,218,098
52-wk High
$71.59
52-wk Low
$45.46

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $96,815.09
Shares Outstanding(Mil.): 1,617.36
Dividend: 0.57
Yield (%): 3.81

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.93 33.11 34.49
EPS (TTM): 3.34 -- --
ROI: 18.66 14.75 14.01
ROE: 181.93 15.86 15.24

S&P 500 ends at seven-month high after Yellen comments

The S&P 500 closed at a 7-month high on Monday as Federal Reserve Chair Janet Yellen painted a mostly upbeat picture of the economy but gave little sense of when a rate hike may be coming. | Video

07 Jun 2016

BRIEF-Abbvie reports 17.93 pct passive stake in Reata as of May 25 - SEC filing

* Abbvie Inc reports 17.93 pct passive stake in Reata Pharmaceuticals Inc as of May 25, 2016 - SEC filing Source text for Eikon: [ID:(http://1.usa.gov/1PeZcPg )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

07 Jun 2016

BRIEF-Moody's downgrades AbbVie to Baa2; stable outlook

* Baa2 rating reflects its large scale with a revenues of about $23 billion, its high margins and its strong cash flow

02 Jun 2016

BRIEF-European Commission approves AbbVie's imbruvica

* European commission approves imbruvica (ibrutinib) for first-line treatment of patients with chronic lymphocytic leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

31 May 2016

Biogen, AbbVie once-monthly MS injection wins U.S. approval

The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

28 May 2016

UPDATE 1-Biogen, AbbVie once-monthly MS injection wins U.S. approval

May 27 The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.

28 May 2016

BRIEF-AbbVie's Humira receives CHMP positive opinion to treat non-infectious uveitis

* AbbVie's Humira receives CHMP positive opinion to treat certain forms of non-infectious uveitis, a disease that can severely impact vision

27 May 2016

BRIEF-Abbvie IL-23 Inhibitor Risankizumab induces remission in Phase II Study

* IL-23 inhibitor risankizumab induces remission in phase ii study in patients with moderate-to-severe crohn's disease

24 May 2016

Coherus says U.S. Patent Office to review AbbVie's Humira

Coherus BioSciences Inc said on Tuesday the U.S. Patent and Trademark Office had agreed to review its petition to make a copy of AbbVie Inc's top-selling arthritis drug Humira.

17 May 2016

BRIEF-AbbVie says Humira protected by many patents covering all aspects of manufacture, formulation and indications

* "we are confident in the validity of our patents and will vigorously defend them"

17 May 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $115.63 -1.75
Pfizer Inc. (PFE.N) $33.97 -0.62
Novartis AG (NOVN.S) CHF75.75 -1.20
Merck & Co., Inc. (MRK.N) $55.88 -1.80
Roche Holding Ltd. (ROG.S) CHF241.00 -5.50
Roche Holding Ltd. (RO.S) CHF246.20 -3.30
Abbott Laboratories (ABT.N) $37.91 -1.72
Eli Lilly and Co (LLY.N) $74.33 +0.39
Sanofi SA (SASY.PA) €69.37 -2.63

Earnings vs. Estimates